Core Viewpoint - China Life Insurance (02628) has shown strong performance with a projected net profit increase of 70% for the first three quarters, estimated between RMB 156.785 billion and RMB 177.689 billion, leading to a significant rise in stock price by 6.04% to HKD 24.94 [1][3]. Financial Performance - The company reported a net profit growth of 70% for Q3, with estimates ranging from RMB 156.785 billion to RMB 177.689 billion [1]. - The stock price surged to HKD 24.94, with a trading volume of HKD 4.224 billion, making it a leader in the insurance sector [1]. Market Sentiment - Analysts expect insurance stocks to perform well, supported by government encouragement for long-term capital investment since September last year [1]. - The positive market sentiment is reflected in the recent performance of China Life and Ping An (2318), both showing substantial price increases [1]. Technical Analysis - Technical indicators show mixed signals, with a sell signal strength of 8, while the RSI is at 62, indicating a 53% probability of price increase [1]. - Key support levels are identified at HKD 22.9 and HKD 22.2, while resistance levels are at HKD 26.6 and potentially HKD 27.7 if broken [1]. Derivative Products Performance - Recent call options related to China Life have performed exceptionally well, with a 58% increase in the Morgan Stanley call option (18417) and a 45% increase in the Bank of China call option (17488) [3]. - This performance highlights the potential for leveraged products in a volatile market [3]. Investment Products - Recommended call options include UBS call option (18990) and HSBC call option (19042), both with a leverage of 5.6 times and a strike price of HKD 28.05 [4]. - For bearish positions, Bank of China put option (19617) and UBS put option (19408) are suggested, with leverage of 5.9 times and 5.6 times, respectively [4].